Carbonation depth measurement of concretes exposed to different curing and preconditioning conditions, using image-processing tools

Specimens of two concretes with different water/cement ratios are subject to various curing and pre-conditioning regimes before being placed in accelerated carbonation conditions. Their carbonation depths are revealed using a phenolphthalein indicator, with image-processing tools used to reduce measurement time, improve accuracy, and eliminate subjectivity of measurements. The results show that specimens cured in water for 28 days show a reduced carbonation depth when compared with those cured in air. Preconditioning with oven-treatment decreased the clarity in the observed carbonation front and had inconsistent effect on the carbonation depth. Image-processing tools were found to be a useful method of consistently measuring carbonation depth using a fixed threshold, particularly in this case where the indication is ambiguous.EPSRC established Career Fellowship titled ‘‘Tailored Reinforced Concrete Infrastructure: Boosting the innate esponse to Chemical and Mechanical Threats” [reference number: EP/N017668/1] and the Doctoral Training Partnership [reference number: EP/N509620/1

Investigations of the size distribution and magnetic properties of nanoparticles of Cu<inf>2</inf>OSeO<inf>3</inf>

Skyrmions in confined geometries have been a subject of increasing interest due to the different properties that they exhibit compared to their bulk counterparts. In this study, nanoparticles of skyrmion-hosting $\text{Cu}_{2}\text{OSeO}_{3}$ have been synthesised using a precipitation method followed by thermal treatment. This enables us to produce nanoparticles whose mean size varies from tens of nanometers to a few micrometers by varying the temperature and duration of the thermal decomposition of the precursor. These sizes span the $\sim 63$~nm diameter of skyrmions in $\text{Cu}_{2}\text{OSeO}_{3}$, allowing investigations into how the magnetic state changes when the size of the geometrical confinement is similar to and smaller than the size of an isolated magnetic skyrmion. AC susceptibility measurements performed on nanoparticles with a size distribution from 15 to 250 nm show a change in the magnetic phase diagram compared to bulk $\text{Cu}_{2}\text{OSeO}_{3}$

Planktonic foraminiferal and calcareous nannofossil biostratigraphy and magnetostratigraphy of the uppermost Campanian and Maastrichtian at Zumaia, northern Spain

The well-exposed and continuous uppermost Cretaceous in the coastal section of Zumaia (northern Spain) crops out as cyclic, deep-water, hemipelagic carbonate-rich sediments of significant geological interest. We present a new, high-resolution calibration of planktonic foraminiferal and calcareous nannofossil biostratigraphic datums, alongside new magnetostratigraphy. Six planktonic foraminiferal zones (Rugoglobigerina rotundata to Pseudoguembelina hariaensis) and nine nannofossil (sub)zones (UC15eTP? to UC20dTP) have been identified, encompassing the uppermost Campanian through uppermost Maastrichtian. Magnetostratigraphic data were obtained from the lower half of the section, where chrons C31r and C31n have been identified; the lithological nature of the upper part of the section provided spurious palaeomagnetic results. According to these data, the Campanian/Maastrichtian (C/M) boundary lies in Chron C31r at Zumaia. Differences between the planktonic foraminiferal and nannofossil datums at Zumaia and those from the Tercis boundary stratotype section (France) suggest that the biostratigraphic criteria used to identify the C/M boundary are problematic. We propose, therefore, two alternative, key biostratigraphic datums with which to determine the stratigraphic position of this boundary: the stratigraphic base occurrence datum (BO) of the planktonic foraminifer Pseudoguembelina palpebra and the top occurrence datum (TO) of the nannofossil Broinsonia parca subsp. constricta. The C31r/C31n magnetic polarity reversal, and the BOs of the planktonic foraminifer Racemiguembelina fructicosa and the nannofossil Lithraphidites quadratus are events that may prove useful in formally defining the lower/upper Maastrichtian boundary

Defining functional interactions during biogenesis of epithelial junctions

In spite of extensive recent progress, a comprehensive understanding of how actin cytoskeleton remodelling supports stable junctions remains to be established. Here we design a platform that integrates actin functions with optimized phenotypic clustering and identify new cytoskeletal proteins, their functional hierarchy and pathways that modulate E-cadherin adhesion. Depletion of EEF1A, an actin bundling protein, increases E-cadherin levels at junctions without a corresponding reinforcement of cell-cell contacts. This unexpected result reflects a more dynamic and mobile junctional actin in EEF1A-depleted cells. A partner for EEF1A in cadherin contact maintenance is the formin DIAPH2, which interacts with EEF1A. In contrast, depletion of either the endocytic regulator TRIP10 or the Rho GTPase activator VAV2 reduces E-cadherin levels at junctions. TRIP10 binds to and requires VAV2 function for its junctional localization. Overall, we present new conceptual insights on junction stabilization, which integrate known and novel pathways with impact for epithelial morphogenesis, homeostasis and diseases

Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease.

Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice

The stroke oxygen pilot study: a randomized control trial of the effects of routine oxygen supplementation early after acute stroke--effect on key outcomes at six months

Introduction: Post-stroke hypoxia is common, and may adversely affect outcome. We have recently shown that oxygen supplementation may improve early neurological recovery. Here, we report the six-month outcomes of this pilot study. Methods: Patients with a clinical diagnosis of acute stroke were randomized within 24 h of admission to oxygen supplementation at 2 or 3 L/min for 72 h or to control treatment (room air). Outcomes (see below) were assessed by postal questionnaire at 6 months. Analysis was by intention-to-treat, and statistical significance was set at p#0.05. Results: Out of 301 patients randomized two refused/withdrew consent and 289 (148 in the oxygen and 141 in the control group) were included in the analysis: males 44%, 51%; mean (SD) age 73 (12), 71 (12); median (IQR) National Institutes of Health Stroke Scale score 6 (3, 10), 5 (3, 10) for the two groups respectively. At six months 22 (15%) patients in the oxygen group and 20 (14%) in the control group had died; mean survival in both groups was 162 days (p= 0.99). Median (IQR) scores for the primary outcome, the modified Rankin Scale, were 3 (1, 5) and 3 (1, 4) for the oxygen and control groups respectively. The covariate-adjusted odds ratio was 1.04 (95% CI 0.67, 1.60), indicating that the odds of a lower (i.e. better) score were non-significantly higher in the oxygen group (p= 0.86). The mean differences in the ability to perform basic (Barthel Index) and extended activities of daily living (NEADL), and quality of life (EuroQol) were also non-significant. Conclusions: None of the key outcomes differed at 6 months between the groups. Although not statistically significant and generally of small magnitude, the effects were predominantly in favour of the oxygen group; a larger trial, powered to show differences in longer-term functional outcomes, is now on-going. Trial Registration: Controlled-Trials.com ISRCTN12362720; Eudract.ema.europa.eu 2004-001866-4

Gauged Flavor Group with Left-Right Symmetry

We construct an anomaly-free extension of the left-right symmetric model, where the maximal flavor group is gauged and anomaly cancellation is guaranteed by adding new vectorlike fermion states. We address the question of the lowest allowed flavor symmetry scale consistent with data. Because of the mechanism recently pointed out by Grinstein et al. tree-level flavor changing neutral currents turn out to play a very weak constraining role. The same occurs, in our model, for electroweak precision observables. The main constraint turns out to come from WR-mediated flavor changing neutral current box diagrams, primarily K - Kbar mixing. In the case where discrete parity symmetry is present at the TeV scale, this constraint implies lower bounds on the mass of vectorlike fermions and flavor bosons of 5 and 10 TeV respectively. However, these limits are weakened under the condition that only SU(2)_R x U(1)_{B-L} is restored at the TeV scale, but not parity. For example, assuming the SU(2) gauge couplings in the ratio gR/gL approx 0.7 allows the above limits to go down by half for both vectorlike fermions and flavor bosons. Our model provides a framework for accommodating neutrino masses and, in the parity symmetric case, provides a solution to the strong CP problem. The bound on the lepton flavor gauging scale is somewhat stronger, because of Big Bang Nucleosynthesis constraints. We argue, however, that the applicability of these constraints depends on the mechanism at work for the generation of neutrino masses.Comment: 1+23 pages, 1 table, 5 figures. v3: some more textual fixes (main change: discussion of Lepton Flavor Violating observables rephrased). Matches journal versio

The impact of different DNA extraction kits and laboratories upon the assessment of human gut microbiota composition by 16S rRNA gene sequencing

Peer reviewedPublisher PD

Correction: PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial. [ISCRTN74418480]

BACKGROUND: The Paracetamol (Acetaminophen) In Stroke (PAIS) study is a phase III multicenter, double blind, randomized, placebo-controlled clinical trial of high-dose acetaminophen in patients with acute stroke. The trial compares treatment with a daily dose of 6 g acetaminophen, started within 12 hours after the onset of symptoms, with matched placebo. The purpose of this study is to assess whether treatment with acetaminophen for 3 days will result in improved functional outcome through a modest reduction in body temperature and prevention of fever.The previously planned statistical analysis based on a dichotomization of the scores on the modified Rankin Scale (mRS) may not make the most efficient use of the available baseline information. Therefore, the planned primary analysis of the PAIS study has been changed from fixed dichotomization of the mRS to a sliding dichotomy analysis. METHODS: Instead of taking a single definition of good outcome for all patients, the definition is tailored to each individual patient's baseline prognosis on entry into the trial. CONCLUSION: The protocol change was initiated becau